GLY-230

Glycadia · Phase 1 active Small molecule

At a glance

Generic name	GLY-230
Sponsor	Glycadia
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 1 Study of Anti-glycation Agent GLY-230 in Healthy Subjects (PHASE1)
Multiple Dose Trial of Anti-glycation Agent GLY-230 in Healthy and Diabetic Subjects (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GLY-230 CI brief — competitive landscape report
GLY-230 updates RSS · CI watch RSS
Glycadia portfolio CI